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The experiments in this study were undertaken to
determine whether inhibition of calpain activity in skel-
etal muscle is associated with alterations in muscle me-
tabolism. Transgenic mice that overexpress human cal-
pastatin, an endogenous calpain inhibitor, in skeletal
muscle were produced. Compared with wild type con-
trols, muscle calpastatin mice demonstrated normal glu-
cose tolerance. Levels of the glucose transporter GLUT4
were increased more than 3-fold in the transgenic mice
by Western blotting while mRNA levels for GLUT4 and
myocyte enhancer factors, MEF 2A and MEF 2D, protein
levels were decreased. We found that GLUT4 can be
degraded by calpain-2, suggesting that diminished deg-
radation is responsible for the increase in muscle
GLUT4 in the calpastatin transgenic mice. Despite the
increase in GLUT4, glucose transport into isolated mus-
cles from transgenic mice was not increased in response
to insulin. The expression of protein kinase B was de-
creased by 60% in calpastatin transgenic muscle. This
decrease could play a role in accounting for the insulin
resistance relative to GLUT4 content of calpastatin
transgenic muscle. The muscle weights of transgenic
animals were substantially increased compared with
controls. These results are consistent with the conclu-
sion that calpain-mediated pathways play an important
role in the regulation of GLUT4 degradation in muscle
and in the regulation of muscle mass. Inhibition of cal-
pain activity in muscle by overexpression of calpastatin
is associated with an increase in GLUT4 protein without
a proportional increase in insulin-stimulated glucose
transport. These findings provide evidence for a physi-
ological role for calpains in the regulation of muscle
glucose metabolism and muscle mass.
The presence of calpains, calcium-activated proteases, in
mammalian cells was first reported over 30 years ago (1). Since
that time at least 14 members of the calpain family have been
identified and their chemistry and biology have been exten-
sively studied (2). It has been proposed that alterations in
calpain activity result in a number of disease states, including
stroke (2, 3), traumatic brain injury (2, 3), Alzheimer’s disease
(2, 3), cataracts (3), limb-girdle muscular dystrophy (2, 3) and
gastric cancer (2). Recent studies of the genetic basis of type 2
diabetes revealed that genetic variation in calpain 10 ac-
counted for a significant component of the genetic risk for
diabetes in a Mexican-American population (4). Subsequent
studies have confirmed the role of calpain 10 as a diabetes
susceptibility gene in some (5) but not all (6–13) populations
studied.
The pathophysiological mechanism(s) whereby genetic vari-
ation in a calpain gene could lead to alterations in glucose
tolerance are not known, and only a limited number of studies
have examined the potential effects of alterations in calpain
activity on insulin secretion or insulin action. These studies
indicate that a reduction in calpain activity caused by calpain
inhibitors induces a state of insulin resistance in isolated mus-
cle strips (14). Pancreatic islets exposed to calpain inhibitors
for 4–6 h demonstrated increased glucose-induced insulin se-
cretion, whereas longer periods of exposure induced significant
defects in insulin secretory responses to glucose and other
secretagogues (14). These studies are limited by the fact that
all experiments were conducted in vitro, and nonspecific effects
of the calpain inhibitors, although unlikely, cannot be com-
pletely excluded. To examine the effects of inhibiting calpain
activity using another in vivo experimental system, we pro-
duced transgenic mice that overexpress the endogenous calpain
inhibitor, calpastatin.
EXPERIMENTAL PROCEDURES
Generation of MCK-hCAST Transgenic Mice—Full-length human
calpastatin (hCAST)1 corresponding to the 673-amino acid isoform de-
scribed in GenBankTM accession number 1611327A was obtained using
human pancreatic islet cDNA as template and amplified with forward
and reverse primers 5-TGG TGC AAC CAG CAA GTC TTC-3 and
5-GGA TGT TCA GAG ACT CAA C-3, respectively. The PCR product
was subcloned into pCR2.1-TOPO (Invitrogen) and the sequence of the
insert confirmed. The insert was excised by digestion with EcoRI and
cloned into the EcoRI site of the mouse muscle-specific creatine kinase
(mMCK) promoter-bovine growth hormone (bGH) polyadenylation sig-
nal vector (15). The 4.28-kb mMCK-hCAST-bGH was excised from the
vector by digestion with HhaI and purified by sucrose gradient centrif-
ugation (Fig. 1). Transgenic mice were generated by microinjection of
transgene DNA into the pronucleus of fertilized single-cell C57BL6
embryos at DNX Transgenic Sciences (Princeton, NJ). Animals were
housed in a room maintained at 23 °C with a fixed 12-h light-dark cycle
* This work was supported in part by National Institutes of Health
Grants DK18966 (to J. O. H.), DK31842 (to K. S. P.), and DK47486 and
20595 (to G. I. B.) as well as by the Diabetes Research and Training
Center at Washington University. The costs of publication of this article
were defrayed in part by the payment of page charges. This article must
therefore be hereby marked “advertisement” in accordance with 18
U.S.C. Section 1734 solely to indicate this fact.
 An investigator of the Howard Hughes Medical Institute.
** To whom correspondence should be addressed: Dept. of Medicine,
Washington University School of Medicine, 660 S. Euclid Ave., Campus
Box 8066, St. Louis, MO 63110. Tel.: 314-362-8061; Fax: 314-362-8015;
E-mail: polonsky@im.wustl.edu.
1 The abbreviations used are: hCAST, human calpastatin; GLUT4,
glucose transporter 4; MEF, myocyte enhancer factor; mMCK, mouse
muscle-specific creatine kinase; EDL, extensor digitorum longus; WT,
wild type; CsTg, calpastatin overexpression transgenic.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 279, No. 20, Issue of May 14, pp. 20915–20920, 2004
© 2004 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 20915
This is an Open Access article under the CC BY license.
and given free access to Purina chow and water. After an overnight fast,
mice were anesthetized by an intraperitoneal injection of pentobarbital
sodium (5 mg/100 g body weight), and the soleus, epitrochlearis, exten-
sor digitorum longus (EDL), and other muscles were excised. All exper-
imental procedures were approved by the Washington University Ani-
mal Study Committee.
DNA, RNA, and Protein Analysis—The mMCK-hCAST transgene
was detected in transgenic mice by PCR analysis of tail DNA using
forward and reverse primers 5-GGC AAC GAG CTG AAA GCT CAT
C-3 and 5-CAG TGA TAC CAG CAA CAC TCT CTC CAC C-3. Total
RNA was isolated from skeletal muscle using TRIzol reagent (Invitro-
gen) and suspended in Dnase- Rnase-free distilled water (Invitrogen).
Mouse GLUT4 mRNA levels were determined by competitive RT-PCR
using GLUT4 forward primer plus nested forward primer 5-TCA ATG
CCC CAC AGA AGG TGT CAA TGG TTG GGA AGG AAA AGG-3 and
reverse primer 5-AAC CAG AAT GCC AAT GAC GAT G-3 as
described previously (34).
Total protein extracts were prepared by homogenizing muscle in 250
mM sucrose containing 20 mM HEPES and 1 mM EDTA, pH 7.4. Protein
was resolved by SDS-PAGE and transferred to nitrocellulose membranes
(Amersham Biosciences). The membranes were blocked overnight at 4 °C
with 5% nonfat milk in phosphate-buffered saline containing 0.1% Tween
20. The membranes were probed with the following primary antibodies:
polyclonal anti-CAST (Calbiochem, La Jolla, CA), anti-GLUT1 and
-GLUT4 (a generous gift from Dr. Mike Mueckler, Washington Univer-
sity), anti-MEF 2A (Santa Cruz Biotechnology, Santa Cruz, CA), and
anti-MEF 2D (Transduction Laboratories, Lexington, KY) as well as anti-
insulin receptor  subunit, anti-insulin receptor substrate-1, anti-insulin
receptor substrate-2, monoclonal anti-Akt/PKB, and anti-phosphatidyl-
inositol 3-kinase, all from Upstate Cell Signaling Solution, Lake Placid,
NY. Horseradish peroxidase-conjugated secondary antibodies were ob-
tained from Jackson ImmunoResearch Laboratories (West Grove, PA),
and reagents for enhanced chemiluminescence were obtained from Am-
ersham Biosciences.
Physiological Studies—Intraperitoneal glucose tolerance tests were
performed following a 4-h fast. Blood was sampled from the tail vein
prior to and 30, 60, and 120 min after injection of dextrose intraperito-
neally (2 g/kg body weight). For glucose transport studies, epitrochle-
aris, soleus, and EDL muscles were removed and allowed to recover
from dissection by incubation in 2 ml of Krebs-Henseleit buffer (KHB)
containing 8 mM glucose, 32 mM mannitol, and 0.1% bovine serum
albumin for 1 h at 35 °C in a shaking incubator. This was followed by 30
min of incubation in the same medium with or without a maximally
effective insulin concentration (2 microunits/ml). The gas phase during
the incubation was 95% O2, 5% CO2. The muscles were then washed for
10 min in KHB containing 40 mM mannitol, 0.1% bovine serum albu-
min, and insulin (if it was present in the previous incubation) to remove
glucose from the extracellular space. Muscles were then transferred to
1.5 ml of KHB containing 3 mM 2-deoxy-D-[1,2-3H]glucose (2DG) (1.5
Ci/ml), 36 mM [14C]mannitol (0.2 Ci/ml), 0.1% bovine serum albumin,
and insulin (if it was present in the previous incubation). Extracellular
space and intracellular 2DG concentration were then determined as
described previously (16).
Measurement of Muscle Weight—The soleus, EDL, tibialis anterior,
gastrocnemius, and quadriceps muscles were dissected out using a
consistent surgical approach. The muscles were weighed immediately
following dissection after blood had been removed from the muscle
surface.
Measurement of Muscle Glycogen Content—Glycogen content was
measured in perchloric acid extracts of muscle by the amyloglucosidase
method (17).
In Vitro Cleavage of Human GLUT4 by Calpain-2—Human GLUT4
(hGLUT4) protein was prepared using a coupled in vitro transcription
and translation system (Promega, Madison, WI). One microgram of the
hGLUT4-plasmid construct pGEM4Z-AMT7 (18) was incubated in the
coupled transcription and translation reaction with 20 Ci of [35S]Met
in a volume of 50 l to generate [35S]-labeled hGLUT4. Unlabeled
hGLUT4 was prepared by using 20 M Met in the coupled transcription
and translation reaction. Four microliters of the coupled transcription
and translation reaction was incubated with 1.7 units of recombinant
rat calpain-2 (Calbiochem) in 20 l of calpain cleavage buffer (150 mM
NaCl, 20 mM Tris-HCl (pH 7.4), 1 mM dithiothreitol, and 0.1% bovine
serum albumin). Calpain was activated by addition of CaCl2 to 5 mM.
Cleavage was terminated after 5 and 30 min by addition of 20 l of
SDS-sample buffer (0.125 M Tris-HCl (pH 6.8), 4% SDS, 20% glycerol,
0.2 M dithiothreitol, and 0.02% bromphenol blue). Samples were heated
at 55 °C for 15 min and analyzed on a 4–20% SDS-PAGE followed by
autoradiography or Western blotting. The Western blot was developed
using a polyclonal anti-GLUT4 antibody generated using a cytoplasmic
12-amino acid C-terminal peptide from mouse GLUT4 (Alpha Diagnos-
tic, San Antonio, TX).
RESULTS
Generation of Transgenic Mice Overexpressing Calpastatin in
Muscle—We obtained five founders (two females and three
males). Human calpastatin was expressed in muscle (soleus
and EDL) from all five founders. The founder used to generate
the mice used in the present experiments showed a substan-
tially greater level of calpastatin expression (20-fold) than
the other founders, which all showed a similar level of overex-
pression. All transgenic mice were heterozygous. All were used
around 4 months of age.
Calpastatin Expression by Western Blot—Overexpression of
human calpastatin in muscles was confirmed by Western blot
(Fig. 2). Although human calpastatin was not expressed in
muscle from WT mice, substantial expression was detected in
transgenic (CsTg) mice.
Mouse Body Weight and Glucose Tolerance—The body weights
of male WT mice averaged 28.1  0.6 g compared with 31.2 
0.5 g for the CsTg group (p 0.01, 8 mice per group, 23–25 weeks
old). For the female mice, body weight averaged 21.8  0.3 g for
the WT group and 23.2  0.4 g for the CsTg group (p 0.01, n 
16 per group, 23–25 weeks old). Differences in the intraperitoneal
glucose tolerance test between the WT and the CsTg mice (WT
versus CsTg: 182.3  6.9 mg/dl versus 197.9  9.3 mg/ dl at
fasting, 189.3  7.0 mg/ dl versus 198.3  10.0 mg/ dl at 2 h after
injection) were not statistically significant.
Insulin Action in Muscle from CsTg Mice—The increase in
2-deoxy-D-[1,2-3H] glucose transport in response to a maxi-
mally effective insulin concentration (2 microunits/ml) was not
significantly different in muscles from CsTg mice as compared
with the WT controls in either EDL (Fig. 3), soleus (data not
shown), or epitrochlearis (data not shown). Basal rates of glu-
cose transport were also not different.
GLUT4 Glucose Transporter Expression—As shown in Fig. 4,
GLUT4 protein content of EDL, soleus, triceps, and tibialis
FIG. 1. Transgene construct used in the production of the
MCK-hCAST transgenic (CsTg) mice.
FIG. 2. Muscle calpastatin expression. Overexpression of human
calpastatin in muscles of CsTg but not WT mice was confirmed by
Western blot.
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anterior muscles was increased more than 3-fold in CsTg mice.
The magnitude of insulin-stimulated muscle glucose transport
is normally directly proportional to muscle GLUT4 content.
This relationship is evident when muscle fiber types with dif-
ferent GLUT4 contents are compared (19), and in muscles that
have undergone an adaptive increase in GLUT4 protein (20–
22). Thus, the finding that stimulated glucose transport was
the same in the CsTg as in the WT muscles despite 3-fold
increases in the GLUT4 protein indicates that the increase in
GLUT4 protein associated with calpastatin overexpression did
not cause the expected increase in glucose transport in re-
sponse to stimulation by insulin.
GLUT4 mRNA Levels—Increases in GLUT4 expression in-
duced by various adaptive stimuli may be mediated at the
transcriptional level, as evidenced by an increased GLUT4
mRNA (23). However, GLUT4 mRNA was significantly de-
creased in muscles from CsTg mice (Fig. 5), suggesting that the
increase in GLUT4 protein was mediated by a post-transcrip-
tional mechanism. Further support for this hypothesis is pro-
vided by the finding that MEF 2A and MEF 2D protein levels
were decreased 50% in the CsTg muscles. Expression of
GLUT4 in striated muscle is dependent on binding of a MEF
2A-MEF 2D heterodimer to the GLUT4 promoter (24). We have
found that stimuli that induce increased GLUT4 expression
also result in increases in MEF 2A and MEF 2D (25). As shown
in Fig. 6, A and B, both MEF 2A and MEF 2D were significantly
decreased in muscles from CsTg mice compared with WT
controls.
GLUT1 Glucose Transporter Expression—The finding that
GLUT4 protein is increased in muscles of the CsTg mice, de-
spite a decrease in GLUT4 mRNA, led us to hypothesize that
GLUT4 is a calpain substrate and that inhibition of calpain by
FIG. 3. Insulin-stimulated 2-deoxyglucose transport. EDL mus-
cles were incubated in the absence or presence of insulin (2 microunits/
ml). Values shown are means  S.E. for seven muscles per group. There
were no significant differences between the WT and the CsTg mice.
FIG. 4. Measurement of immunoreactive GLUT4. GLUT4 pro-
tein was determined by Western blotting in EDL, soleus, triceps, and
tibialis anterior using a rabbit polyclonal antibody directed against the
C terminus of GLUT4. Values are means  S.E. for eight muscles per
group. *, p 0.001; **, p 0.0001; #, p 0.00001; ##, p 0.000002 versus
WT mice.
FIG. 5. Measurement of GLUT4 mRNA. The sequence of compet-
itor RNA was identical to cDNA amplified by RT-PCR except for a
155-bp internal deletion (161–315). Mouse skeletal muscle total RNA
was reverse-transcribed into cDNA and amplified using hybrid forward
primer and reverse primer. Values are means  S.E. for eight muscles
per group. *, p 0.003.
FIG. 6. Measurement of immunoreactive MEF 2A and 2D. A,
MEF 2A. B, MEF 2D. Myocyte enhancer factors MEF 2A and 2D were
measured by Western blot. Expression of GLUT4 in striated muscle is
dependent on binding of MEF 2A-2D heterodimer to the GLUT4 pro-
moter. Values are means  S.E. Triceps (n  8), tibialis anterior (n 
8), and gastrocnemius (n  6). *, p 0.05; **, p 0.01; ***, p 0.001.
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calpastatin is responsible for the increase in GLUT4. If this
hypothesis is correct, one might also expect to see an increase
in GLUT1 protein because its amino acid sequence is similar to
that of GLUT4 (26). We, therefore, measured the GLUT1 pro-
tein level and found that it was also increased in skeletal
muscle of the CsTg mice. Although highly significant (controls,
1.04  0.14 versus CsTg, 1.66  0.14 arbitrary units, mean 
S.E. for 16 muscles per group, p 0.004), the magnitude of the
increase was smaller than that of GLUT4.
Muscle Glycogen—Glucose transport is the primary rate-
limiting step that determines the rate and extent of muscle
glycogen accumulation (27). Increases in muscle GLUT4 are,
therefore, generally associated with an increase in muscle gly-
cogen content (20–22, 28, 29). Muscle glycogen concentrations
were significantly increased in muscles of the CsTg mice,
20.4  0.9 mol/g EDL WT muscle compared with 46.0  2.7
mol/g EDL CsTg muscle.
Effect of Muscle Glycogen Depletion on Glucose Transport—
Accumulation of glycogen in muscle may induce insulin resist-
ance. To determine whether the increase in glycogen in muscles
from CsTg mice was masking an increase in muscle glucose
transport in CsTg muscles, we exposed muscles to hypoxia for
80 min, a maneuver that reduces glycogen. The glucose con-
centration in the incubation medium for the CsTg muscles was
also reduced compared with the incubations for the WT mus-
cles (2 and 8 mM glucose, respectively). This approach markedly
reduced glycogen concentrations to 7 mol/g muscle wet
weight. However, even after a reduction in muscle glycogen
there were no significant differences in glucose transport in-
duced by 2 microunits/ml insulin and hypoxia in the EDL and
the soleus muscles of the CsTg compared with the WT mice
(data not shown). Thus, the increase in GLUT4 resulting from
calpain inhibition was not associated with a parallel increase in
muscle glucose transport.
Proteins of the Insulin Signaling Pathway—As a next step in
our investigation of the mechanism responsible for the relative
insulin resistance of the CsTg muscles, we measured the levels
of some of the proteins of the insulin signaling pathway. Ex-
pression of the insulin receptor, insulin receptor substrates 1
and 2, and phosphatidylinositol 3-kinase proteins was similar
in skeletal muscle of the transgenic and wild type mice (Fig. 7).
However, there was a remarkable (60%) decrease in protein
kinase B in skeletal muscle of the CsTg mice (Fig. 7). This
finding could explain why insulin-stimulated glucose transport
is not increased in CsTg muscle despite a 3-fold increase in
GLUT4.
Cleavage of Human GLUT4 in Vitro by Calpain-2—To de-
termine whether human GLUT4 is a calpain cleavage sub-
strate, we incubated 35S-labeled recombinant hGLUT4 with
purified calpain-2. The recombinant hGLUT4 has a mass of
43.7 kDa, and incubation with activated calpain-2 generated
a protein with an estimated mass of 37.2 kDa (Fig. 8A). This
fragment was not identified by an antibody that binds to an
epitope at the C terminus of GLUT4 (Fig. 8B), suggesting the
calpain-2 cleavage site is located in the C-terminal portion of
GLUT4. The mass of the cleavage product suggests that the
calpain-sensitive site is about 60–70 residues from the C
terminus.
Effects on Muscle Mass—To determine whether overex-
pression of calpastatin affected muscle mass, muscles were
systematically weighed in 23–25-week-old mice. Weight of
EDL and soleus muscles was increased 12% (EDL, males),
33% (EDL, females), 17% (soleus, males), and 19% (soleus,
females), respectively (Fig. 9A). Similar increases in mass
were present in the other muscles, including the tibialis
anterior (42% in males, 47% in females), gastrocnemius (13%
in males, 14% in females), and quadriceps (21% in males, 14%
in females) (Fig. 9B). Total muscle protein was increased in
proportion to muscle weight in EDL (WT versus CsTg: 1.96 
0.10 mg versus 2.40  0.10 mg, p 0.01) and soleus (WT
versus CsTg: 1.58  0.08 mg versus 1.85  0.10 mg, p 0.05).
FIG. 8. Human GLUT4 is cleaved by calpain-2 in vitro. A, 35S-
labeled recombinant hGLUT4 was incubated with calpain-2 for 5 and
30 min. The samples were subjected to SDS-PAGE and autoradiogra-
phy. B, unlabeled recombinant GLUT4 was incubated with calpain-2.
The GLUT4 protein was identified by Western blot using an anti-C-
terminal GLUT4 antibody (GLUT4). The arrowhead indicates the
GLUT4 fragment generated on incubation with calpain-2.
FIG. 7. Measurement of immunore-
active insulin receptor (IR), insulin
receptor substrates (IRS) -1 and -2,
protein kinase B (PKB), and phos-
phatidylinositol 3-kinase (PI 3-K).
Values are means  S.E. (n  6, gastro-
cnemius muscle); *, p 0.0006.
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DISCUSSION
The present study was designed to determine whether re-
ducing calpain expression in muscle is associated with alter-
ations in muscle glucose metabolism. A transgenic mouse with
muscle-specific overexpression of calpastatin was used as the
experimental model. The transgenic mice did not have overt
changes in glucose tolerance and did not appear to be insulin-
resistant in vivo. However, in vitro studies of muscle revealed
a number of interesting effects of calpastatin overexpression.
One important change observed was a greater than 3-fold
increase in GLUT4 protein detected by Western blotting. The
increase was found consistently in a number of different mus-
cles, including EDL, soleus, triceps, and tibialis anterior. It is
most likely that the increase in GLUT4 is due to a reduction in
the rate of GLUT4 breakdown for the following reasons.
GLUT4 mRNA was not increased and was actually decreased,
as were protein levels for MEF 2A and 2D, two transcription
factors that mediate induction of GLUT4 expression (24). Our
hypothesis is that GLUT4 serves as a calpain substrate and
that the reduction in calpain activity resulting from increased
expression of calpastatin leads to the increase in GLUT4 levels
observed. The results of additional experiments that demon-
strated that GLUT4 is a substrate for calpain-2 in vitro are
consistent with this idea, as is the finding that GLUT1, which
has an amino acid sequence similar to that of GLUT4 (26), was
also increased.
Previous experiments have shown that pharmacological in-
hibition of calpain causes insulin resistance of glucose trans-
port in skeletal muscle (14). In view of this observation, we
expected that overexpression of calpastatin, an endogenous
calpain inhibitor, would result in severe skeletal muscle insulin
resistance. Our finding that insulin-stimulated glucose trans-
port was normal in CsTg muscles provides evidence suggesting
that the greater than 3-fold increase in GLUT4 protein induced
by calpastatin overexpression compensated for insulin resist-
ance caused by inhibition of calpain activity. Maximally insu-
lin-stimulated glucose transport is normally directly propor-
tional to the GLUT4 protein content of a muscle (19, 21, 22).
Therefore, the finding that glucose transport rates were the
same in muscles of the WT and CsTg mice, despite the higher
GLUT4 content of the CsTg muscles, provides evidence for a
severe resistance to stimulation of glucose transport of the
CsTg muscles relative to their GLUT4 content. Our finding of
an 60% reduction in protein kinase B expression in CsTg
FIG. 9. Muscle weight. Muscles of 23–
25-week-old mice were carefully dissected
and weighed. Values are means  S.E. for
six to eight muscles per group. *, p 0.05;
**, p  0.0001.
Calpain Regulates Muscle Mass and GLUT4 Turnover 20919
skeletal muscle raises the possibility that an attenuation of
insulin signaling via this step may play a role in mediating the
relative insulin resistance. The marked decrease in expression
of MEF 2A, MEF 2D, and protein kinase B provides evidence
suggesting that the large increase in GLUT4 directly or by
means of a secondary effect, such as the increase in glycogen,
results in suppression of the expression of these proteins.
It used to be thought that calpains play a major role in
muscle protein degradation only when cytosolic Ca2 homeo-
stasis is disturbed by trauma or ischemia and in muscular
dystrophies (30, 31). The role of calpains in protein turnover in
normal skeletal muscle is still unclear. However, evidence is
accumulating that calpains mediate the initiating steps in the
turnover of myofibrillar proteins. It appears that calpains are
responsible for release of filaments from the myofibrils, making
them available for degradation by the proteasome (32). It was
recently reported that overexpression of calpastatin in skeletal
muscle protects mice against the muscle atrophy associated
with hindlimb unloading (33). The present finding that cal-
pastatin overexpression results in skeletal muscle hypertrophy
provides evidence that calpains are also involved in normal
skeletal muscle protein turnover.
The implications of the results of this study for our under-
standing of the pathophysiology of type 2 diabetes are unclear.
Genetic variation in a specific calpain, calpain 10, has been
associated with altered risk for type 2 diabetes (4, 5). Although
calpastatin inhibits the activity of calpains I and II, it has not
been determined whether it has similar effects on calpain 10.
Nevertheless, our results provide further evidence that inhibi-
tion of calpain activity causes insulin resistance. This finding
implies that calpain plays a role in the stimulation of glucose
transport. Our results also provide additional new information
indicating that inhibition of calpain activity in skeletal muscle
results in an increase in GLUT4 protein and causes muscle
hypertrophy. These findings strongly suggest that calpains
play important roles in GLUT4 and skeletal muscle proteolysis.
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